Choose a Topic
- All Topics
- ASH 2017
- AML
- MDS
- Lymphomas and CLL
- Older Patient HCT
- Sickle Cell Disease
- Post-Transplant
- GVHD
- Patient Eligibility
- CIBMTR Publications
- Cord Blood
- Pediatric HCT
- ALL
- CML
- Multiple Myeloma
- Neuroblastoma
- Non-Malignant Disorders
- HLA Matching
- Preparative Regimens
- BMT CTN Publications
- Unrelated Donor HCT
- ASH 2018
- ASH 2020
Recent Research
Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
Allogeneic CAR T cell therapy may be a safe and feasible treatment for relapsed refractory multiple myeloma patients
January 2023
Mailankody S, et al. – A novel research study published in Nature Medicine reviewed the safety and feasibility of allogeneic chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma patients. Results showed more than half of the patients responded to treatment despite expected adverse events, showing promise as a safe and effective option for patients with aggressive disease.